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Abstract Background: Intraoperative lidocaine is widely used in controlling discomfort
during cataract surgery. However, recent studies have confirmed the toxic
effect of lidocaine on ganglion cells. Ropivacaine is an anesthetic recently
introduced in clinical practice that couples a long anesthetic effect with a mild
vasoconstrictive action.
Objective: The aim of this study was an in vitro evaluation of the efficacy
of ropivacaine in reducing the degenerative effects usually observed during
lidocaine treatment.
Methods: Ropivacaine and lidocaine toxicity has been evaluated in murine
fibroblasts 3T6 by measuring percentage of cell death, cell growth inhibition,
and DNA degradation. The choice of this cellular line is motivated by
the presence of a complete apoptotic system that can be assimilated to the
endothelium precursor cells.
Results:We observed that lidocaine 0.25% decreases cell viability and causes
DNA degradation in murine fibroblasts 3T6, whereas ropivacaine 0.5% does
not cause any cellular or molecular degenerative effect.
Conclusions: Our in vitro studies confirm that ropivacaine is less toxic than
lidocaine to these cells. Therefore, in vivo studies in the anterior chamber
could be useful to evaluate the effects of ropivacaine versus lidocaine in
intracameral anesthesia in cataract surgery.
Introduction
In the last few years, the frequency of cataract
surgery has greatly increased, possibly due to an
increase in life expectancy.[1] The current anes-
thesia practice does not call for total anesthesia
except in pediatrics and handicapped subjects.
Use of local anesthesia (retrobulbar, peribulbar,
sub-Tenon’s) is limited, even though it is im-
portant in eye surgery of anxious subjects and
elderly patients who cannot easily control ocular
movements. To prevent severe but rare compli-
cations, such us globe perforation, optic nerve
injury, muscular paresis, diplopia, eyelid ptosis,
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and retinal vascular occlusion, safer anesthesia
techniques were investigated. Fichman[2] has in-
troduced topical anesthesia with xylocaine, which
has proved to be an effective and safe technique
with good postoperative recovery.[2-4] However,
intraoperative discomfort and pain, particularly
during phacoemulsification and intraocular lens
implantation, have necessitated the association
with subconjunctival, retrobulbar, or peribulbar
anesthesia.[5,6] Gills et al.[7] have reported en-
couraging results in reducing intraoperative
discomfort during cataract surgery through the
intracameral injection of 1% unpreserved lido-
caine in the presence of topical anesthesia. The
same authors have found in their studies that
intraocular lidocaine does not damage corneal
endothelium (cell count and corneal thickness).
These data were confirmed by Kim et al.[8]
in both human endothelium and laboratory
animals; however, a transient endothelial cell
edema was observed during lidocaine infusion.
This was easily evaluated by specular microscopy
and electronic scansion microscopy.[8] Gills
et al.[9] have reported a transient loss of vision in
4 cases in a total of over 15 000 patients. This
was essentially due do a dialysis of the posterior
capsule with lidocaine interfering with ganglion
cell function. Recent in vitro and in vivo studies
have confirmed the toxic effect of lidocaine
on ganglion cells.[10,11] Furthermore, the short
duration of the local anesthetic makes adminis-
tration of a second dose during cataract surgery
necessary, thus increasing the risk of toxicity.
Ropivacaine, which has recently been introduced
in clinical surgery, can represent a valid alterna-
tive to lidocaine in intracameral anesthesia. In
fact, ropivacaine presents the speculative advan-
tages of a long-duration and bland vasoconstrictive
effect.[12]
In our study, we investigated an in vitro
evaluation of the efficacy of the local toxicity of
ropivacaine versus lidocaine by utilizing murine
fibroblasts 3T6 in culture. This cell line was
chosen because of its similarities to the endothe-
lium precursors and because apoptosis can
be easily induced and controlled.[13,14] In fact,
occurrence of apoptotic phenomena is diagnostic
of generalized toxic effect at cellular level.[15]
Materials and Methods
Cell Cultures
The murine 3T6 fibroblasts are a stable line of
derma fibroblasts. These fibroblasts compare
well with endothelial cell precursors. Cell cul-
tures were routinely maintained on Dulbecco’s
modified Eagle’s medium (DMEM) and 10%
heat-inactivated fetal bovine serum. Cells were
maintained at 37C in a humidified atmosphere
of 5% CO2 and 95% air.
Unless stated otherwise, to assess apoptotic
and/or necrotic phenomena, 5 · 105 cells were
plated in 10 cm Petri dishes and left untreated for
24 hours before experimentation began.
Treatment Protocols
Ropivacaine (Naropine) is a well tolerated,
effective, long-duration, local anesthetic. Ropi-
vacaine in low concentrations, unlike lidocaine,
reduces cutaneous blood flow and produces
bland vasoconstriction.[12] Ropivacaine and
lidocaine were dissolved in isotonic saline
buffer (phosphate buffered saline [PBS]) and
made up to a final concentration of 10mmol/L
and 5mmol/L, respectively. To assess toxicity,
cells were exposed to ropivacaine or lidocaine for
24 hours.
Measurement of Cell Viability
Cell viability as well as cell growth was meas-
ured by trypan blue exclusion. Briefly, 5 · 105
cells were centrifuged for 5 minutes at 100 g. The
cell pellet was resuspended in 1mL PBS. An
equal amount of cell suspension and 0.4% trypan
blue were mixed. After an incubation time of 3–5
minutes, a drop of cell suspension/trypan blue
was applied to a hemacytometer. Unstained
(viable) and stained (unviable) cells were counted
and the percentage of viability determined.
DNA Degradation
The effect of the treatment was monitored
after extraction of DNA according to Hirt[16] gel
electrophoresis and visualization with ethidium
bromide.
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Statistical Analysis
Quantitative values were presented as mean–
SD. Significant differences between sets of values
for control and test groups were assessed by a one-
way ANOVA using a studentNewman-Keuls post
hoc test. A p-value refers to a comparison of a
measured parameter in the experimental group
with that of the appropriate control. Significance
was set at p< 0.05.
Results and Discussion
The effects of lidocaine and ropivacaine
treatment on cell viability are shown in figure 1a.
In particular, cells were treated for 24 hours with
lidocaine 5mmol/L. After 24 hours, the medium
was replaced and cell viability measured after
48 hours. Figure 1a shows that during such treat-
ment, lidocaine decreased cell viability to 65%.
A partial cellular recovery was observed after
72 hours and 96 hours with a cell viability of 82%
and 84%, respectively (figure 1a). By contrast,
during the treatment, ropivacaine 10mmol/L, cell
viability did not alter and remained about 95%
(figure 1a). Lidocaine and ropivacaine concen-
trations were chosen from a dose-response analysis
of doses ranging from 1 to 20mmol/L (unpub-
lished observations, Professor Scarsella).
Cytotoxic effects of lidocaine and ropivacaine
were determined by measuring cell proliferation.
Figure 1b shows that, compared with the pro-
liferation curve of untreated cells, lidocaine
caused a significant inhibition. In particular, after
24 hours, there was almost a 50% decrease in the
number of cells due to the toxic effect (figure 1b).
By contrast, ropivacaine caused only an initial
inhibition of cell proliferation that was reduced
after 96 hours of treatment (figure 1b); a time
where the differences between ropivacaine and
lidocaine were evident. Finally, figure 1c shows
that lidocaine caused a DNA degradation re-
presented by an evident smear of heterogeneous
fragments after extraction and gel electro-
phoresis. The production of these fragments is
typical in necrotic phenomena (figure 1c, lane d).
By contrast, ropivacaine caused only a minor
degradation of DNA (figure 1c, lane b).
Intracameral injection of lidocaine 1% in ad-
dition to topical anesthesia was an important
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Fig. 1. Cytotoxic effects of lidocaine and ropivacaine. (a) Percentage cell viability after 48, 72, and 96 hours. (b) Number of viable
cells after 0, 24, 48, 72, and 96 hours. (c) Gel electrophoresis (lane a shows the DNA molecular weight marker; lane b shows
ropivacaine-treated cells; lane c shows control untreated cells; and lane d shows lidocaine-treated cells). * p <0.05 vs control, - p <0.05 vs
ropivacaine.
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advancement in ocular anesthesia during cataract
surgery.[7,9] However, safer and newer drugs are
being investigated in ocular anesthesia to improve
surgical techniques. In particular, ropivacaine
may represent a safer alternative to lidocaine,
thanks to its long-term efficacy and modest vaso-
constrictive action, which is usually an advanta-
geous side effect in anterior segment surgery.
By contrast, lidocaine causes vasodilation and has
a short anesthetic effect (about 10 minutes).
Therefore, supplemental injections of anesthetic in
anterior chamber surgery to obtain the desired
anesthesia are often reported, thereby increasing
the risk of toxicity and impairing surgical proce-
dure. The duration of the anesthetic effect is
related to the extent of protein binding, which
in ropivacaine is 94%, while in lidocaine it is
about 64%. In addition, in ropivacaine, there is a
marked difference in effect between sensitive and
motor blocks that enables surgeons to use very low
doses of the drug to inhibit only sensitive func-
tion. Therefore, the long duration and the vaso-
constrictive action typical of ropivacaine are a
definite advantage in anterior chamber surgery.
Our results indicate that, in addition to the dura-
tion and vasoconstriction effects reported in this
study, ropivacaine has the advantage that it does
not cause any cellular damage.
In particular, some authors have observed that
perfusion of lidocaine l% in human and murine
endothelial corneal cells causes a transient cel-
lular edema.[8,17] In our experimental model,
comparable with endothelial cells, ropivacaine
versus lidocaine does not present degenerative
effects even at a concentration as high as
10mmol/L.
Conclusions
In the light of our results, neither drug caused
apoptosis; however, lidocaine did give rise to
evident necrosis. Therefore, lidocaine may have
relevant cytotoxic effects for the endothelium in
cataract surgery. Our data are in agreement with
the cytotoxic effects observed by Grosskreutz
et al.[10] both in vitro and in vivo. It is there-
fore reasonable to conclude that ropivacaine
is safer than lidocaine because, at very low con-
centrations, it can assure long duration of action
coupled with mild but useful vasoconstriction,
without causing any degenerative effects on en-
dothelial cells.
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